JWH-018 in rhesus monkeys: Differential antagonism of discriminative stimulus, rate-decreasing, and hypothermic effects

European Journal of Pharmacology

Volumn 740, Issue , 2014, Pages 151-159

  Rodriguez, Jesse S ^a   McMahon, Lance R ^a  

^a University of Texas Health Science Center   (United States)

Author keywords

Cannabinoid; Drug discrimination; Hypothermia; JWH 018; Schild analysis; 9 tetrahydrocannabinol

Indexed keywords

1-PENTYL-3-(1-NAPHTHOYL)INDOLE; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 3-(2-HYDROXY-4-(1,1-DIMETHYLHEPTYL)PHENYL)-4-(3-HYDROXYPROPYL)CYCLOHEXANOL; BENZOXAZINE DERIVATIVE; CANNABINOID; CANNABINOID 1 RECEPTOR; CANNABINOID RECEPTOR AGONIST; CANNABINOID RECEPTOR ANTAGONIST; CYCLOHEXANOL DERIVATIVE; DRONABINOL; INDOLE DERIVATIVE; MORPHOLINE DERIVATIVE; NAPHTHALENE DERIVATIVE; PIPERIDINE DERIVATIVE; PYRAZOLE DERIVATIVE; RIMONABANT;

ANIMAL; BODY TEMPERATURE; CHEMICALLY INDUCED; DISCRIMINATION LEARNING; DRUG EFFECTS; HYPOTHERMIA; INSTRUMENTAL CONDITIONING; MALE; METABOLISM; RHESUS MONKEY;

ANIMALS; BENZOXAZINES; BODY TEMPERATURE; CANNABINOID RECEPTOR AGONISTS; CANNABINOID RECEPTOR ANTAGONISTS; CANNABINOIDS; CONDITIONING, OPERANT; CYCLOHEXANOLS; DISCRIMINATION LEARNING; DRONABINOL; HYPOTHERMIA; INDOLES; MACACA MULATTA; MALE; MORPHOLINES; NAPHTHALENES; PIPERIDINES; PYRAZOLES; RECEPTOR, CANNABINOID, CB1;

EID: 84906053619     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2014.06.023     Document Type: Article

References (35)

1. O. Arunlakshana, and H.O. Schild Some quantitative uses of drug antagonists Br. J. Pharmacol. Chemother. 14 1959 48 58
2. R.L. Balster, and W.R. Prescott Delta 9-tetrahydrocannabinol discrimination in rats as a model for cannabis intoxication Neurosci. Biobehav. Rev. 16 1992 55 62
3. L.K. Brents, E.E. Reichard, S.M. Zimmerman, J.H. Moran, W.E. Fantegrossi, and P.L. Prather Phase I hydroxylated metabolites of the K2 synthetic cannabinoid JWH-018 retain in vitro and in vivo cannabinoid 1 receptor affinity and activity PLoS One 6 2011 e21917
4. S.R. Childers Activation of G-proteins in brain by endogenous and exogenous cannabinoids AAPS J. 8 2006 E112 E117
5. R. Cinar, and M. Szücs CB1 receptor-independent actions of SR141716 on G-protein signaling: coapplication with the mu-opioid agonist Tyr-D-Ala-Gly-(NMe)Phe-Gly-ol unmasks novel, pertussis toxin-insensitive opioid signaling in mu-opioid receptor-Chinese hamster ovary cells J. Pharmacol. Exp. Ther. 330 2009 567 574
6. D.R. Compton, M.D. Aceto, J. Lowe, and B.R. Martin in vivo characterization of a specific cannabinoid receptor antagonist (SR141716A): inhibition of delta 9-tetrahydrocannabinol-induced responses and apparent agonist activity J. Pharmacol. Exp. Ther. 277 1996 586 594 (Pubitemid 27168965)
7. J. De Vry, and K.R. Jentzsch Discriminative stimulus effects of the structurally novel cannabinoid CB1/CB2 receptor partial agonist BAY 59-3074 in the rat Eur. J. Pharmacol. 505 2004 127 133 (Pubitemid 39535684)
8. A.N. Gifford, M. Bruneus, S.J. Gatley, R. Lan, A. Makriyannis, and N.D. Volkow Large receptor reserve for cannabinoid actions in the central nervous system J. Pharmacol. Exp. Ther. 288 1999 478 483 (Pubitemid 29119654)
9. B.C. Ginsburg, D.R. Schulze, L. Hruba, and L.R. McMahon JWH-018 and JWH-073: Δ9-tetrahydrocannabinol-like discriminative stimulus effects in monkeys J. Pharmacol. Exp. Ther. 340 2012 37 45
10. J.W. Huffman, G. Zengin, M.J. Wu, J. Lu, G. Hynd, K. Bushell, A.L. Thompson, S. Bushell, C. Tartal, D.P. Hurst, P.H. Reggio, D.E. Selley, M.P. Cassidy, J.L. Wiley, and B. Martin Structure-activity relationships for 1-alkyl-3-(1-naphthoyl)indoles at the cannabinoid CB1 and CB2 receptors: steric and electronic effects of naphthoyl substituents. New highly selective CB2 receptor agonists Bioorg. Med. Chem. 13 2005 89 112 (Pubitemid 39575695)
11. L. Hruba, B.C. Ginsburg, and L.R. McMahon Apparent inverse relationship between cannabinoid agonist efficacy and tolerance/cross-tolerance produced by Δ9-tetrahydrocannabinol treatment in rhesus monkeys J. Pharmacol. Exp. Ther. 342 2012 843 849
12. Institute of Laboratory Animal Resources Guide for the Care and Use of Laboratory Animals 8th ed. 2011 Institute of Laboratory Animal Resources, Commission on Life Sciences, National Research Council Washington, DC
13. T.U.C. Järbe, C. Li, S.K. Vadivel, and A. Makriyannis Discriminative stimulus functions of methanandamide and delta(9)-THC in rats: tests with aminoalkylindoles (WIN55,212-2 and AM678) and ethanol Psychopharmacology 208 2010 87 98
14. B.D. Kangas, M.S. Delatte, V.K. Vemuri, G.A. Thakur, S.P. Nikas, K.V. Subramanian, V.G. Shukla, A. Makriyannis, and J. Bergman Cannabinoid discrimination and antagonism by CB(1) neutral and inverse agonist antagonists J. Pharmacol. Exp. Ther. 344 2013 561 567
15. T. Kenakin Pharmacologic Analysis of Drug-Receptor Interaction 1997 Raven Press New York
16. B.R. Martin, D.R. Compton, B.F. Thomas, W.R. Prescott, P.J. Little, R.K. Razdan, M.R. Johnson, L.S. Melvin, R. Mechoulam, and S.J. Ward Behavioral, biochemical, and molecular modeling evaluations of cannabinoid analogs Pharmacol. Biochem. Behav. 40 1991 471 478
17. L.R. McMahon Characterization of cannabinoid agonists and apparent pA2 analysis of cannabinoid antagonists in rhesus monkeys discriminating Delta9-tetrahydrocannabinol J. Pharmacol. Exp. Ther. 319 2006 1211 1218
18. L.R. McMahon Apparent affinity estimates of rimonabant in combination with anandamide and chemical analogs of anandamide in rhesus monkeys discriminating Delta9-tetrahydrocannabinol Psychopharmacology 203 2009 219 228
19. 9-tetrahydrocannabinol treatment in rhesus monkeys: differential tolerance and cross-tolerance among cannabinoids Br. J. Pharmacol. 162 2011 1060 1073
20. L.R. McMahon, M.R. Amin, and C.P. France SR 141716A differentially attenuates the behavioral effects of delta9-THC in rhesus monkeys Behav. Pharmacol. 16 2005 363 372 (Pubitemid 41404807)
21. L.R. McMahon, B.C. Ginsburg, and R.J. Lamb Cannabinoid agonists differentially substitute for the discriminative stimulus effects of Delta(9)-tetrahydrocannabinol in C57BL/6J mice Psychopharmacology 198 2008 487 495 (Pubitemid 351754667)
22. H. Müller, W. Sperling, M. Köhrmann, H.B. Huttner, J. Kornhuber, and J.M. Maler The synthetic cannabinoid Spice as a trigger for an acute exacerbation of cannabis induced recurrent psychotic episodes Schizophr. Res. 118 2010 309 310
23. C.A. Paronis, S.P. Nikas, V.G. Shukla, and A. Makriyannis Δ(9)-Tetrahydrocannabinol acts as a partial agonist/antagonist in mice Behav. Pharmacol. 23 2012 802 805
24. R.G. Pertwee Receptors and channels targeted by synthetic cannabinoid receptor agonists and antagonists Curr. Med. Chem. 17 2010 1360 1381
25. M. Rinaldi-Carmona, F. Barth, M. Héaulme, D. Shire, B. Calandra, C. Congy, S. Martinez, J. Maruani, G. Néliat, D. Caput, P. Ferrara, P. Soubrié, J.C. Brelière, and G. Le Fur SR141716A, a potent and selective antagonist of the brain cannabinoid receptor FEBS Lett. 350 1994 240 244 (Pubitemid 24268029)
26. A.B. Schneir, and T. Baumbacher Convulsions associated with the use of a synthetic cannabinoid product J. Med. Toxicol. 8 2012 62 64
27. K.A. Seely, A.L. Patton, C.L. Moran, M.L. Womack, P.L. Prather, W.E. Fantegrossi, A. Radominska-Pandya, G.W. Endres, K.B. Channell, N.H. Smith, K.R. McCain, L.P. James, and J.H. Moran Forensic investigation of K2, Spice, and "bath salt" commercial preparations: A three-year study of new designer drug products containing synthetic cannabinoid, stimulant, and hallucinogenic compounds Forensic. Sci. Int. 233 2013 416 422
28. J.R. Simmons, C.G. Skinner, J. Williams, C.S. Kang, M.D. Schwartz, and B.K. Wills Intoxication from smoking "spice Ann. Emerg. Med. 57 2011 187 188
29. M. Spaderna, P.H. Addy, and D.C. D'Souza Spicing things up: synthetic cannabinoids Psychopharmacology 228 2013 525 540
30. R.J. Tallarida, and R.B. Raffa Receptor regulation, competitive antagonism and pA2 Life Sci. 51 1992 PL61 PL65
31. D. Vearrier, and K.C. Osterhoudt A teenager with agitation: higher than she should have climbed Pediatr. Emerg. Care 26 2010 462 465
32. J.L. Wiley, D.R. Compton, D. Dai, J.A. Lainton, M. Phillips, J.W. Huffman, and B.R. Martin Structure-activity relationships of indole- and pyrrole-derived cannabinoids J. Pharmacol. Exp. Ther. 285 1998 995 1004 (Pubitemid 28277896)
33. J.L. Wiley, D. Matthew Walentiny, R.E. Vann, and C.Y. Baskfield Dissimilar cannabinoid substitution patterns in mice trained to discriminate Δ(9)-tetrahydrocannabinol or methanandamide from vehicle Behav. Pharmacol. 22 2011 480 488
34. 2mechanism J. Pharmacol. Exp. Ther. 340 2012 433 444
35. A.M. Young, M.A. Masaki, and C. Geula Discriminative stimulus effects of morphine: effects of training dose on agonist and antagonist effects of mu opioids J. Pharmacol. Exp. Ther. 261 1992 246 257